Apopharma SRL
Apopharma reported total assets of 702,319 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of Apopharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +10 % Total assets +8 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apopharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 198,622 € | ||||
| Equity | 178,027 € | ||||
| Cash | 501,775 € | ||||
| EBITDA | 225,088 € | ||||
| Total assets | 702,319 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 05 Sep 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Apopharma's financial analysis
- Solvency25.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apopharma
Apopharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0871.799.376
- VAT number
- BE0871799376
- Peppol
- Registered · 0208:0871799376 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Feb 2005
- Registered office
- 1970 Wezembeek-Oppem
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apopharma (SRL) has been based in Wezembeek-Oppem since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 198,622 € and equity of 178,027 €; its revenue is not published. Its solvency stands at 25.3%, below the median of its sector (44.2%).
Companies similar to Apopharma
Companies in the same business, of comparable size and area, outside its group.
- NEW Pharmacie Saint Antoine Retail sale of pharmaceutical products Etterbeek · balance sheet 701,883 €
- Apotheek Neveux-Roelans Retail sale of pharmaceutical products Sint-Niklaas · balance sheet 702,929 €
- West Pharma Retail sale of pharmaceutical products Anderlecht · balance sheet 701,649 €
- Mepharma Retail sale of pharmaceutical products Merelbeke-Melle · balance sheet 701,340 €
- Houmanfarma Retail sale of pharmaceutical products Meise · balance sheet 700,955 €
- Masy Pharma Retail sale of pharmaceutical products Vilvoorde · balance sheet 700,251 €
- Pharma Cite Retail sale of pharmaceutical products Montigny-le-Tilleul · balance sheet 705,229 €
- Meer Apotheek Retail sale of pharmaceutical products Hoogstraten · balance sheet 705,802 €
Frequently asked questions about Apopharma
What is the revenue of Apopharma?
Apopharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apopharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0871799376 for Apopharma, if the company is VAT-registered. Its company number (CBE) is 0871.799.376.
Where is the registered office of Apopharma?
According to the CBE register, the registered office of Apopharma is in 1970 Wezembeek-Oppem.
What is the equity of Apopharma?
At the close of the 2025 financial year, the equity of Apopharma amounts to 178,027 €, a solvency of 25.3% of total assets.
Who manages Apopharma?
The register lists 2 active mandates at Apopharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apopharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →